Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Systemic adalimumab induces peripheral corneal infiltrates: a case report

  • Alexandre Matet1, 2,
  • Alejandra Daruich1, 2,
  • Talal Beydoun1,
  • Jacques Cosnes3 and
  • Jean-Louis Bourges1Email author
BMC Ophthalmology201515:57

https://doi.org/10.1186/s12886-015-0047-6

Received: 27 January 2014

Accepted: 29 May 2015

Published: 6 June 2015

Abstract

Background

Tumor necrosis factor-alpha inhibitors are widely used agents in the treatment of immune disorders such as rheumatoid arthritis and inflammatory bowel disease. Despite their anti-inflammatory action, paradoxical drug-induced inflammatory events have been occasionally associated with the use of infliximab, etanercept, and in a lesser extent adalimumab. However, eye involvement is uncommon and anterior uveitis is the only reported ocular adverse manifestation. It can be induced by etanercept, but has also been described during adalimumab therapy. We present here the first report of recurrent peripheral corneal infiltrates following subcutaneous injections of adalimumab.

Case presentation

A 34 year-old Caucasian woman with Crohn’s disease presented to the emergency department with bilateral red eyes and discomfort 36 hours after she received her bimonthly dose of subcutaneous adalimumab. Examination revealed bilateral peripheral corneal infiltrates with characteristic features of immune infiltrates. Symptoms and infiltrates regressed after topical corticosteroid therapy, but recurred after each adalimumab injection over the following weeks.

Conclusion

Paradoxical immune reactions associated with tumor necrosis factor-alpha inhibitors may result either from hypersensitivity mechanisms, or from immune-complex deposition via anti-adalimumab antibodies. Both mechanisms could explain this newly described manifestation. Care should be taken to search for corneal infiltrates in the event of red eye symptoms during adalimumab therapy since they respond to topical corticosteroids and do not necessarily prompt the discontinuation of the immunosuppressive therapy.

Keywords

Cornea Adalimumab Tumor necrosis factor-alpha inhibitor Adverse effects Peripheral infiltrate Crohn's disease

Background

Adalimumab is a recombinant monoclonal antibody that inhibits tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine. It is commonly employed for several immune-mediated disorders, including inflammatory bowel disease, ankylosing spondylitis and rheumatoid arthritis, with favorable safety reports [1, 2]. Yet, adverse events are progressively identified. Their diagnosis can be challenging since they often share features with the underlying inflammatory condition for which the drug is prescribed. The most common adverse manifestations include dermatitis, fever, interstitial pneumonia or vasculitis, but ocular involvement is very infrequent. To date, anterior uveitis is the only ocular adverse event registered in the literature [3]. In this report, we describe recurrent and bilateral peripheral corneal infiltrates caused by subcutaneous injections of adalimumab. To the best of our knowledge, this is the first report of adalimumab-induced corneal infiltrates.

Case presentation

A 34 year-old Caucasian woman with Crohn’s disease presented to the eye emergency department at our institution with bilateral red eyes and discomfort. She had been wearing soft daily-wear contact lenses with monthly replacement schedule for the past 10 years. She had stopped wearing them 3 months before her visit as a consequence of fluctuating dry eye symptoms. She also reported a recent episode of interface dermatitis on her right ankle, confirmed by internal medicine specialists. She developed HLA-B27-negative ileal Crohn's disease at age 18, and required two intestinal resections at age 20 and 25 for stricturing disease. Thereafter, inflammation had been satisfactorily controlled by oral azathioprine. At the age of 30, 4 years before her visit to our emergency department, recurrence of clinical symptoms led to a switch from oral azathioprine to subcutaneous adalimumab. She had since been receiving 40 mg of subcutaneous adalimumab every 2 weeks.

Prior to the current episode, the patient had been evaluated biennially for 10 years by her attending ophthalmologist in the context of contact lens use. At each visit, she had been screened for ocular signs related to her inflammatory bowel disease. Her corneal status was unremarkable at all examinations. In particular, the patient did not have any history of meibomian gland disease or marginal keratitis.

Ocular symptoms occurred 36 hours following the last adalimumab administration and were more intense in her left eye. The patient did not report any loss of vision. In addition to diffuse conjunctival hyperemia and peri-limbal injection, slit-lamp examination of her left eye revealed a white-grayish anterior stromal infiltrate near the inferior corneal margin, with a diameter of 0.3 mm (Fig. 1: a, b, white arrow), and a string of smaller lesions along the superior margin (Fig. 1: c, d, black arrows). We observed a single small lesion in her right eye, located along the superior nasal limbus. All signs shared characteristics of immune infiltrates: a hazy fluorescein stain with intact epithelium, a clear margin between infiltrate and limbus, and subtle corneal neovascularization. The anterior stromal localization of the lesions was visible on slit-lamp biomicroscopy (Additional file 1: Figure S1). Symptoms improved and infiltrates cleared with topical dexamethasone T.I.D (Fig. 1: e). Two weeks later, 24 hours after the next injection of adalimumab, the patient returned with recurrent symptoms. Clinical findings were identical to the first examination in both eyes and again disappeared with topical dexamethasone (Additional file 2: Figure S2 and Additional file 3: Figure S3). After a third episode that was managed in the same way, and at the patient’s request, sporadic ocular symptoms were considered acceptable with regard to the control of bowel inflammation, and adalimumab therapy was not discontinued. For the treatment of the few recurrences that occurred over the following months, dexamethasone was successfully replaced by rimexolone to reduce the risk of ocular hypertension. Two months after the first visit, trough serum adalimumab was 7.4 μg/mL, within therapeutic range (1.9 to 8.3 μg/mL) [4].
Fig. 1

Peripheral corneal infiltrates secondary to systemic adalimumab for Crohn’s disease. a. Left eye of a 34 year-old female patient showing a grayish infiltrate near the inferior corneal margin (white arrow) observed 2 days after subcutaneous administration of adalimumab. b. Magnified view of the inferior infiltrate (white arrow) showing subtle corneal vascularization. c and d. String of smaller infiltrates along the superior corneal margin (black arrows). e. Regression of infiltrates after one week of topical dexamethasone T.I.D.

Discussion

The features and timing of these recurrences strongly point to adalimumab injections as their causative factor. To the best of our knowledge, there is no previous report of peripheral corneal inflammation secondary to adalimumab.

The infiltrates could have been a manifestation of the inflammatory bowel disease itself. Ocular manifestations during Crohn’s disease indeed include scleritis, episcleritis, uveitis and less frequently peripheral corneal infiltrates, that may complicate sceritis [5, 6]. However, scleritis was absent in this case, and Crohn’s disease was quiescent. In fact, the residual serum level of adalimumab fell within therapeutic range [4], indicating efficient disease control.

Soft contact lens wear is unlikely to be the source of the peripheral infiltrates in this patient, since they had been discontinued 3 months before the onset of eye redness and discomfort. Intact corneal epithelium over the infiltrates and efficient control by steroids also rule out infectious keratitis. The absence of eyelid inflammation and the timing of recurrences do not support the hypotheses of meibomian gland disease, marginal keratitis or phlyctenulosis.

Ironically, TNF-α inhibitors are known to generate adverse inflammatory reactions despite their immunosuppressive action. Among them, adalimumab induces 3.5 % of hypersensitivity events, the lowest rate within this therapeutic class [7]. Cutaneous manifestations are the most frequent. They include type I hypersensitivity reactions at injection sites [8], paradoxical inflammation leading to “psoriasiform” lesions [9] and various types of dermatitis including interface dermatitis [10], as developed by our patient. Some reports also point to adalimumab as the causative agent in drug-induced interstitial pneumonia [11, 12], fever [13] or vasculitis [14, 15]. Yet, ocular adverse events have been rarely described following adalimumab, and the only reported manifestation is acute anterior uveitis [3].

Remarkably, in a recent United States-based registry analysis of uveitis induced by TNF-α inhibitors, adalimumab accounted for only 3 % of cases, far less than infliximab (24 %) and etanercept (73 %) [3]. Scleritis has also been described after etanercept [16], but not after adalimumab or infliximab. However, except for etanercept these agents are considered safe enough for the treatment of refractory inflammatory eye disease, including peripheral ulcerative keratitis [17], scleritis [18] and uveitis [19, 20].

Regarding its pathogenic mechanism, the formation of peripheral corneal infiltrates usually requires either immune-complex deposition or type III hypersensitivity [21]. In this patient, the presence of anti-adalimumab antibodies was very unlikely, since they would have been associated with low drug serum levels and treatment failure due to the neutralization of adalimumab molecules [22]. For this reason, laboratory testing was technically not feasible because the high residual adalimumab level would have neutralized any circulating anti-adalimumab antibodies.

Conclusion

In this report, the patient developed symptomatic, recurrent corneal peripheral infiltrates after repeated subcutaneous administration of adalimumab, a TNF-α inhibitor. These infiltrates resulted either from an immune reaction to adalimumab, or from a paradoxical exacerbation of Crohn’s disease following adalimumab injections. Given the growing number of individuals under TNF-α inhibitor therapy, sterile corneal infiltrates should be meticulously looked for in the event of red eye symptoms. They respond to topical corticosteroid therapy without discontinuation of adalimumab.

Consent

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Declarations

Acknowledgement

We wish to thank the patient for allowing us to report the case, and Dr Kattayoon Hashemi from the Cornea and Refractive surgery Unit, Jules-Gonin Eye Hospital, Lausanne, Switzerland, for proofreading the manuscript.

Authors’ Affiliations

(1)
Department of Ophthalmology, Hotel-Dieu Hospital, AP-HP, and Sorbonne Paris Cité University, Paris Descartes faculty of medicine
(2)
Department of ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des aveugles
(3)
Department of Gastroenterology, Saint-Antoine Hospital, AP-HP, and Pierre et Marie Curie University

References

  1. Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn’s disease. Am J Med. 2011;124(4 Suppl):e1–e18.View ArticlePubMedGoogle Scholar
  2. Haraoui B, Cividino A, Stewart J, Guerette B, Keystone EC. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study. BMC Musculoskelet Disord. 2011;12:261.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248–52.View ArticlePubMedGoogle Scholar
  4. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–40.View ArticlePubMedGoogle Scholar
  5. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9.View ArticlePubMedGoogle Scholar
  6. Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis. 2009;15:29–34.View ArticlePubMedGoogle Scholar
  7. Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2012;108:123–4.View ArticleGoogle Scholar
  8. Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008;144:1190–4.View ArticlePubMedGoogle Scholar
  9. Tammaro A, Persechino S, Abruzzese C, Narcisi A, Cortesi G, Parisella FR, et al. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab. Int J Immunopathol Pharmacol. 2012;25:499–501.PubMedGoogle Scholar
  10. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39:481–92.View ArticlePubMedGoogle Scholar
  11. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496–503.View ArticlePubMedGoogle Scholar
  12. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Haruna S, Ushida N, Kawana K, Tanaka Y: Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Mod Rheumatol Jpn Rheum Assoc. 2014;24:390–8Google Scholar
  13. Gonzalo-Garijo AM, Rodriguez-Nevado I, Perez-Calderon R, Sanchez-Vega S, Perez-Rangel I. Severe Cutaneous Reaction and Fever Due to Adalimumab. Ann Allergy Asthma Immunol. 2010;105:490–1.View ArticlePubMedGoogle Scholar
  14. Bakkour W, Coulson IH, Sahasrabudhe N. Adalimumab-induced medium-sized vessel vasculitis. Clin Exp Dermatol. 2012;37:562–4.View ArticlePubMedGoogle Scholar
  15. Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc Mayo Clin. 2012;87:739–45.View ArticlePubMedGoogle Scholar
  16. Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea H-K, Prati C, Orcel P, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39:233–9.View ArticlePubMedGoogle Scholar
  17. Pham M, Chow CC, Badawi D, Tu EY. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease. Am J Ophthalmol. 2011;152:183–8. e2.View ArticlePubMedGoogle Scholar
  18. Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94:579–83.View ArticlePubMedGoogle Scholar
  19. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–6.View ArticlePubMedGoogle Scholar
  20. Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Für Klin Exp Ophthalmol. 2013;251:1601–6.View ArticleGoogle Scholar
  21. Mondino BJ. Inflammatory diseases of the peripheral cornea. Ophthalmology. 1988;95:463–72.View ArticlePubMedGoogle Scholar
  22. Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA J Am Med Assoc. 2011;305:1460–8.View ArticleGoogle Scholar

Copyright

© Matet et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement